Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis.

Lenalidomide with or without ESA and/or G-CSF (Lenalidomide+/-ESA+/-G-CSF) (OR 1.92, 95% CI 0.80 – 4.59; P-score: 0.43), ESA plus deferasirox (OR 1.77, 95% CI 0.27 – 11.76; P-score: 0.39), oral azacitidine (CC-486; OR 1.66, 95% CI 0.95 – 2.90; P-score: 0.37), imetelstat (OR 1.63, 95% CI 0.87 – 3.06; P-score: 0.36), lenalidomide (OR 1.45, 95% CI 0.82 – 2.58; P-score: 0.28) and amifostine (OR 1.41, 95% CI 0.28 – 7.18; P-score: 0.31) did not reach statistical significance ( Figures 2A-a ; Appendix 7 ).

also in 111,027 other papers